The National Cancer Institute (NCI) seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.
To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity. The National Cancer Institute's Laboratory of Molecular Biology seeks interested parties to co-develop and commercialize immunotoxins using toxin domains lacking human B cell epitopes.
The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.
Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.
This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. The National Cancer Institute's Surgery Branch seeks interested parties to license or co-develop the use of T cell receptors (TCRs) cloned against the SSX-2 antigen for the treatment of cancer.
Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.
Novel Furoquinolinediones derivatives may act as an anti-cancer agent by the inhibition of tyrosyl-DNA phosphodiesterase 2 (TDP2), an enzyme involved in DNA repair and transcription factor activation. These Furoquinolinediones derivatives may also be used in combination therapies to effectively kill cancer cells.
Researchers at the National Cancer Institute (NCI) have developed several novel small-molecule inhibitors directed against HPPK, a bacterial protein, as potential antimicrobial agents. The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.
Researchers at the National Cancer Institute (NCI) have developed nucleic-acid-based nanoparticle that can be adapted for RNA interference (RNAi), molecular imaging, or a combination thereof. The invention nanoparticles can be used as therapeutics in the treatment of cancer, whichthe NCI seeks parties to license or co-develop.
Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010
It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use.
Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity. NCI’s Cancer and Inflammation Program seeks partners interested in licensing or co-development of synthetic, highly potent cell-permeable inhibitors of Ras that bind to the protein directly.
Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished. The National Cancer Institute Laboratory of Experimental Immunology seeks parties interested in licensing a topical antibiotic formulation to accelerate wound healing.
Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of cnidarins.
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.